Literature DB >> 9705834

Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells.

T Moriyama1, H Kataoka, R Hamasuna, K Yokogami, H Uehara, H Kawano, T Goya, H Tsubouchi, M Koono, S Wakisaka.   

Abstract

Recent findings suggest that hepatocyte growth factor/scatter factor (HGF/SF) contributes to the malignant progression of human gliomas. We investigated the effect of HGF/SF on vascular endothelial growth factor (VEGF) expression of c-Met/HGF receptor-positive human glioma cell lines. Treatment of the glioma cells with various concentrations of HGF/SF resulted in an enhanced secretion of VEGF proteins accompanying increased transcription of VEGF mRNA in a dose-dependent fashion. Since malignant gliomas frequently co-express HGF/SF and its receptor, these results suggest that HGF/SF could act as an indirect angiogenic factor through autocrine induction of VEGF expression and secretion in malignant gliomas.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9705834     DOI： 10.1006/bbrc.1998.9078

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  21 in total

1.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Expression of hepatocyte growth factor activator inhibitor type 1 in endothelial cells.

Authors:  Yutaka Akiyama; Miyuki Nagai; Wataru Komaki; Kousuke Marutsuka; Yujiro Asada; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2006-08       Impact factor: 4.174

3.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

4.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

5.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides.

Authors:  Sheng-hua Chu; Zhi-an Zhu; Xian-hou Yuan; Zhi-qiang Li; Pu-cha Jiang
Journal:  J Neurooncol       Date:  2006-04-29       Impact factor: 4.130

Review 7.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 8.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

9.  Receptor-type protein tyrosine phosphatase beta (RPTP-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (HGFR/Met) function.

Authors:  Yiru Xu; Wei Xia; Dustin Baker; Jin Zhou; Hyuk Chol Cha; John J Voorhees; Gary J Fisher
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

10.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.